Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery | News
Search Refinements

Drug Delivery News

View news from other Pharmaceutical sectors:
46-60 of 2292 results
Pfizer plans to launch REMICADE biosimilar in US in November
Pfizer said it will begin shipping INFLECTRA (infliximab-dyyb)for injection, a biosimilar of REMICADE (infliximab) to wholesalers in the US in late November 2016.
Drug Research > Drug Delivery > News
TFS buys dermatology specialist SCIderm
TFS has acquired German dermatology specialist SCIderm.
Drug Research > Drug Delivery > News
NICE recommends AstraZeneca's osimertinib drug for people with lung cancer
The UK's National Institute for Health and Care Excellence (NICE) said that AstraZeneca's osimertinib drug, also known as Tagrisso, should be made available on the Cancer Drugs Fund (CDF).
Drug Research > Drug Delivery > News
PAREXEL agrees to acquire ExecuPharm
PAREXEL International has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry.
Drug Research > Drug Delivery > News
UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq
By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharmaceuticals’ Strensiq (asfotase alfa) drug to treat rare inherited bone disorder in children.
Drug Research > Drug Delivery > News
Facebook’s Mark Zuckerberg announces $3bn funding to help cure diseases
By PBR Staff Writer
Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, have committed to invest over $3bn during the next decade to work on preventing, curing or managing all diseases.
Drug Research > Drug Delivery > News
EMA validates BMS' type II variation application for Opdivo in advanced form of bladder cancer
The European Medicines Agency (EMA) validated Bristol-Myers Squibb's (BMS) type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
Drug Research > Drug Delivery > News
Catalent agrees to buy Pharmatek Laboratories
By PBR Staff Writer
Drug delivery solutions provider Catalent has agreed to acquire Pharmatek Laboratories, a US-based contract drug development and clinical manufacturing firm, for an undisclosed sum.
Drug Research > Drug Delivery > News
ImmuPharma to open site in Mauritius for trial of Lupus treatment
ImmuPharma has provided a further update on the progress of its Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.
Drug Research > Drug Delivery > News
Dr. Reddy's Laboratories launches Bupropion HCl extended-release tablets, USP (SR) in US
Dr. Reddy’s Laboratories has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCl) Sustained-Release Tablets in the US market approved by the US Food & Drug Administration (USFDA).
Drug Research > Drug Delivery > News
Caisson Biotech seeks buyer for HEPtune drug-delivery platform
Caisson Biotech has appointed Pickwick Capital Partners to assist in the sale of the HEPtune drug-delivery platform.
Drug Research > Drug Delivery > News
Impax recalls one lot of Lamotrigine Orally Disintegrating Tablet 200 mg
Impax Laboratories has issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg.
Drug Research > Drug Delivery > News
Marken secures new pharmaceutical license for Moscow depot
Marken has secured a new pharmaceutical license from the Russian Federation for its Moscow depot.
Drug Research > Drug Delivery > News
Supernus secures FDA tentative approval for expanded label of Trokendi XR
The US Food and Drug Administration (FDA) has granted tentative approval to Supernus Pharmaceuticals' Supplemental New Drug Application (sNDA) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
Drug Research > Drug Delivery > News
Tissue Regeneration engineered mesenchymal stromal cells advance monoclonal antibody therapy
Tissue Regeneration Therapeutics announced that a team of Canadian researchers has for the first time shown that TRT's engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves.
Drug Research > Drug Delivery > News
46-60 of 2292 results